Diarrhea Drug Imodium Swept Up in Opioid Crisis Under FDA Rules
- FDA asks J&J to limit number of antidiarrhea pills per box
- Large dosages of Imodium can produce opioid-like euphoria
How America's Opioid Crisis Spiraled Out of Control
This article is for subscribers only.
Boxes of Johnson & Johnson’s popular antidiarrheal drug Imodium could soon contain far fewer caplets, under a U.S. Food and Drug Administration request that seeks to limit access of drug abusers to pills that can produce an opioid-like high.
The FDA has asked J&J to reduce the number of caplets in over-the-counter retail packages of Imodium to provide for short-term diarrhea treatment, a move would be followed by makers of generic versions of Imodium.